<DOC>
	<DOCNO>NCT02106390</DOCNO>
	<brief_summary>The purpose trial evaluate immunogenicity , safety tolerability rMenB+OMV NZ MenACWY vaccines healthy infant , concomitantly administer 3 , 5 , 7 13 month age , compare either alone .</brief_summary>
	<brief_title>Safety Immunogenicity Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>1 . Healthy 3month old infant ( 85119 day , inclusive ) time Visit 1 whose parents/legal guardian give write informed consent nature study explain . 2 . Available visit schedule study . 3 . In good health determine medical history , physical examination clinical judgment investigator . 1 . History previous immunization meningococcal vaccine vaccine contain meningococcal antigen ( ) time enrollment . 2 . Previous know suspected disease cause N. meningitidis . 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection colonization . 4 . History severe allergic reaction previous vaccination , hypersensitivity component vaccine . 5 . Known suspected autoimmune disease impairment/alteration immune system result , example : Chronic administration immunosuppressant immunemodifying drug since birth ( 3 month prior ) . ( For corticosteroid , mean prednisone , equivalent , ≥ 0.5 mg/kg/day ≥ 10 mcg/day child 2 year . Inhaled topical steroid allow ) , Immune deficiency disorder , know HIV infection . 6 . Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation since birth . 7 . History progressive severe neurologic disorder , seizure disorder Guillan Barré syndrome ( exception : one selflimited febrile seizure acceptable ) . 8 . History bleed disorder consider contraindication intramuscular injection blood draw . 9 . Child 's parent ( ) legal guardian ( ) able comprehend follow require study procedure whole period study . 10 . Receipt investigational nonregistered product since birth ( 3 month prior ) expect receive study period . 11 . Family member household member site research staff . 12 . Any clinicallysignificant chronic progressive disease accord judgment investigator ( pulmonary , cardiovascular , renal , hepatic endocrine functional abnormality ) congenital anomaly/known cytogenic disorder ( e.g. , Down 's syndrome ) . 13 . History illness/condition , opinion investigator , might interfere result study pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>85 Days</minimum_age>
	<maximum_age>119 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Meningitis</keyword>
</DOC>